Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07644130
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere UniversityNot Yet RecruitingNot Applicable
NCT07644130Not Yet Recruiting
Not Applicable
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere University
NCT07643961
Outpatient Versus Inpatient Management of Mild Acute PancreatitisCenter for Traumatology and Major Burns, Ben ArousNot Yet RecruitingNot Applicable
NCT07643961Not Yet Recruiting
Not Applicable
Outpatient Versus Inpatient Management of Mild Acute PancreatitisCenter for Traumatology a...
NCT07644234
Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic StrokeSichuan Provincial People's HospitalNot Yet RecruitingPhase 4
NCT07644234Not Yet Recruiting
Phase 4
Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patie...Sichuan Provincial People...
NCT07646561
Transcranial Doppler in Preeclampsia and Its Complications.University Tunis El ManarCompleted
NCT07646561Completed
—
Transcranial Doppler in Preeclampsia and Its Complications.University Tunis El Manar
NCT07644962
Research Project on the Interaction Between Immune Function and Infectious Diseases in Older Adults and the Development of Prevention and Control StrategiesHuashan HospitalNot Yet Recruiting
NCT07644962Not Yet Recruiting
—
Research Project on the Interaction Between Immune Function and Infectious Disea...Huashan Hospital
NCT07645742
Pilot Study of Intermittent Fasting With Immune Checkpoint InhibitorsWest Virginia UniversityNot Yet RecruitingNot Applicable
NCT07645742Not Yet Recruiting
Not Applicable
Pilot Study of Intermittent Fasting With Immune Checkpoint InhibitorsWest Virginia University
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07644780
Evaluation of an Intervention for Optimizing Pregnant Women's Adherence to Maternal Multiple Micronutrients SupplementsNutrition InternationalCompletedNot Applicable
NCT07644780Completed
Not Applicable
Evaluation of an Intervention for Optimizing Pregnant Women's Adherence to Mater...Nutrition International
NCT07645560
A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After Acute Ischemic StrokeBeijing Tiantan HospitalNot Yet RecruitingPhase 2
NCT07645560Not Yet Recruiting
Phase 2
A Phase 2b Trial of Lesion Network Mapping-Guided cTBS for Motor Recovery After...Beijing Tiantan Hospital
NCT07644104
Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation SurgeryZhejiang UniversityNot Yet RecruitingNot Applicable
NCT07644104Not Yet Recruiting
Not Applicable
Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation SurgeryZhejiang University
NCT07644026
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet Recruiting
NCT07644026Not Yet Recruiting
—
HBV Reactivation Prediction Model in Allo-HSCTInstitute of Hematology &...
NCT07646067
Closed Loop Glucose Control in a Simulated ICU SettingEmory UniversityNot Yet RecruitingNot Applicable
NCT07646067Not Yet Recruiting
Not Applicable
Closed Loop Glucose Control in a Simulated ICU SettingEmory University
NCT07646028
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLCNot Yet RecruitingPhase 1
NCT07646028Not Yet Recruiting
Phase 1
R-3750 in Patients With Late-Stage Acute Respiratory Distress Syndrome (ARDS)Rise Therapeutics LLC
NCT07644325
Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior Carpal Ligament BiopsyClinique Saint Jean, FranceRecruitingNot Applicable
NCT07644325Recruiting
Not Applicable
Concordance for Transthyretin Amyloidosis Between Synovial Biopsy and Anterior C...Clinique Saint Jean, Fran...
NCT07645469
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid LeukemiaFred Hutchinson Cancer CenterNot Yet RecruitingPhase 1
NCT07645469Not Yet Recruiting
Phase 1
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Di...Fred Hutchinson Cancer Ce...
NCT07644624
Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Surgery (SLIDY)Hospital Universitari de BellvitgeNot Yet RecruitingNot Applicable
NCT07644624Not Yet Recruiting
Not Applicable
Sling vs. Dynamic Shoulder Stabilizer After Soft Tissue Shoulder Instability Sur...Hospital Universitari de...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646249
VENtilation Modalities During Transport of PostoperatIve CRITically Ill Patients to the ICUAzienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di AlessandriaNot Yet Recruiting
NCT07646249Not Yet Recruiting
—
VENtilation Modalities During Transport of PostoperatIve CRITically Ill Patients...Azienda Ospedaliera SS. A...
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07645222
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D CompanyNot Yet RecruitingPhase 1
NCT07645222Not Yet Recruiting
Phase 1
PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLCHansoh BioMedical R&D Com...
Result Breakdown
Not yet recruiting16 (80%)
Completed2 (10%)
Recruiting2 (10%)
not_applicable9 (45%)
Not Specified4 (20%)
Phase 14 (20%)
Phase 22 (10%)
Phase 41 (5%)